Lundbeck CEO: two to three projects will fail every year

We might as well get used to it: There will be a greater number of failed studies from Lundbeck in the time to come. But the company has time to wait for the winning ticket as sales of its key products are on the rise – and with years of patent protection ahead, CEO Kåre Schultz is playing it cool.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MedWatch-indeks: Endnu en tung uge for biotekaktierne

Nedturen ser ud til at fortsætte for de danske biotekaktier, som alle oplevede kursfald i uge 47. Novo Nordisk ender for en efterhånden sjælden gangs skyld på toppen i MedWatch-indekset, efter at have givet markedet tiltro til fremtiden på sin kapitalmarkedsdag.

Latest Top picks in English

Related articles